XENE — Xenon Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1582313 ·
British Columbia, Canada
Last close
$52.40
Market Cap
$5.07B
52W High
$59.99
52W Low
$50.91
ADV30
1,229,470
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -112,328,000 | -102,302,000 | 1,386,810,000 | 545,867,000 | 48,991,000 |
| Dec 2025 | 0 | — | -109,767,000 | -105,261,000 | 633,163,000 | 199,163,000 | 51,403,000 |
| Sep 2025 | 0 | — | -96,336,000 | -90,896,000 | 607,836,000 | 104,514,000 | 48,325,000 |
| Jun 2025 | 0 | — | -94,229,000 | -84,706,000 | 674,281,000 | 135,381,000 | 40,303,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-306,363,000
Investing CF
$-223,794,000
Financing CF
$958,975,000
CapEx
$-889,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.70
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,347,682,000
Inventory
—
Receivables
$1,165,000
ST Investments
$548,880,000
EBIT TTM
$-412,660,000
Pretax Income TTM
$-385,147,000
Interest Exp TTM
—
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-410,188,992
Free Cash Flow
$-186,274,496
Enterprise Value
$3,978,018,816
Total Cash
$1,094,747,008
Total Debt
$7,491,000
Shares Out
96,665,550
Trailing EPS
$-4.70
Book Value
$7.27
ROE
-37.5%
ROA
-24.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,500,000 | -373,070,000 | -345,910,000 | 633,163,000 | 51,403,000 | — | -279,118,000 |
| Dec 2024 | 0 | -279,298,000 | -234,330,000 | 798,139,000 | 43,236,000 | — | -181,389,000 |
| Dec 2023 | 0 | -214,054,000 | -182,393,000 | 964,798,000 | 36,877,000 | — | -151,112,000 |
| Dec 2022 | 9,434,000 | -129,143,000 | -125,373,000 | 754,146,000 | 32,649,000 | — | -101,028,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.01
Max Pain — expiry 2026-07-17
max pain strike: $55.00 · spot: $52.24 · call oi: 10,888 · put oi: 313
Expected Move to 2026-07-17:
±$7.00
(13.40%) —
implied range
$45.24 –
$59.24
· ATM straddle on $52.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | $5.08B | $253.25 | — |
| TVTX | Travere Therapeutics, Inc. | $5.00B | $53.80 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.18B | $16.24 | — |
| GRFS | Grifols SA | $5.19B | $7.62 | — |
| GIKLY | Grifols SA | $4.81B | $5.69 | — |
News headlines (Yahoo Finance, 1h cache)
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate
2026-06-11 17:11 · Yahoo
UPGUYS Founders Mat Rezaei and Ramin Behzadi Named 2026 EY Entrepreneur Of The Year® Pacific Region Finalists as Canada's Leading TRT Platform Scales Nationwide
2026-06-09 11:30 · Yahoo
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-29 20:01 · Yahoo
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)
2026-05-23 02:31 · Yahoo
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
2026-05-18 17:44 · Yahoo
SCANBO® FEATURED IN GOVERNMENT OF BRITISH COLUMBIA'S 2026 LIFE SCIENCES ECOSYSTEM MAP
2026-05-12 18:27 · Yahoo
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway
2026-05-11 15:13 · Yahoo
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?
2026-05-11 08:13 · Yahoo
Xenon Pharmaceuticals Q1 Earnings Call Highlights
2026-05-09 08:07 · Yahoo
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
2026-05-08 16:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.